CJC-1295 vs Sermorelin
A comprehensive, data-driven comparison of CJC-1295 (Modified GRF 1-29) and Sermorelin (GHRH 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Both hit the same receptor (GHRH) and do the same basic job - tell the pituitary to release growth hormone. The difference is what the pharmaceutical industry did with each. Sermorelin was FDA approved in 1997, marketed as Geref for pediatric GH deficiency, then voluntarily pulled from the market in 2008. The withdrawal was a business decision, not a safety signal - Merck-Serono decided it was not commercially viable against recombinant HGH. That distinction matters: sermorelin is still legally available through 503A compounding pharmacies as an off-label prescription, running $150-350 per month through legitimate anti-aging clinics.
CJC-1295 never reached approval. It is a longer-acting sermorelin variant with structural modifications (the no-DAC version has four amino acid substitutions, the DAC version adds a maleimide linker that binds albumin). It hit FDA Category 2 in September 2023 and is on the pending reclassification list from the February 2026 announcement. Research-grade raw peptide runs $35-70 per month. No pharmacy can legally make it for patients.
The practical choice, if you want GHRH-pathway GH optimization with a legitimate supply chain, is sermorelin. It has 28 years of off-label use, pediatric pharmacokinetic data from the Geref era, and a compounding pathway that survives current FDA enforcement. CJC-1295 has a longer half-life and is more potent on paper, but those advantages matter less when you cannot legally obtain it. The table below breaks down half-lives, dosing frequency, legal status, and typical clinical programs for each compound.
Side-by-Side Comparison
| Property | CJC-1295 Modified GRF 1-29, DAC:GRF | Sermorelin GHRH 1-29, GRF 1-29 |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Withdrawn (off-label use continues) |
| Category | Growth Hormone | Growth Hormone |
| Primary Use | Growth hormone optimization and anti-aging | Growth hormone deficiency and anti-aging |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $150 - $350/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1-2mg twice weekly (with DAC) | 200-500mcg daily before bed |
| Frequency | Twice weekly | Daily |
| Mechanism | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone | Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Moderate |
| Clinical Trial Phase | N/A | N/A |
Key Differences
- 1CJC-1295 is generally more affordable ($35 - $70/mo) compared to Sermorelin ($150 - $350/mo).
- 2CJC-1295 is dosed twice weekly, while Sermorelin is daily.
- 3Sermorelin has moderate-quality evidence, while CJC-1295 has emerging-quality evidence.
Which Is Better For...
CJC-1295
More budget-friendly option with lower monthly costs
CJC-1295
More convenient dosing schedule (twice weekly)
CJC-1295
Fewer commonly reported side effects
Sermorelin
Stronger clinical evidence base to support its use
Sermorelin is the pragmatic GHRH peptide here: legally compoundable through 503A pharmacies, clinically familiar, and backed by roughly 28 years of off-label use since the 2008 Geref withdrawal. CJC-1295 is more potent per dose and longer-acting on paper, but it is FDA Category 2 and not available through any legitimate pharmacy. If you want a supervised GH-optimization protocol through an anti-aging or HRT clinic, sermorelin is almost certainly what you will be prescribed, with programs running $150-350 per month. CJC-1295 is a research-chemical path with no clinical supply chain and no way to verify what you are injecting.
Get CJC-1295 or Sermorelin Online
Vetted telehealth providers that prescribe either peptide.
PeptideVS may earn a commission from providers listed below. Our editorial data is independent - see our disclosure for details.
Eden
Sponsored
Research peptide telehealth covering recovery, longevity, and growth-hormone protocols.
- Non-GLP-1 peptide catalog (GHRH, healing, longevity)
- Licensed prescriber intake, US pharmacy fulfillment
- Multi-peptide stacks available
We may earn a commission when you sign up.
PlushCare
Sponsored
Primary-care telehealth with broad Rx coverage and same-day appointments.
- Broad primary-care scope, not GLP-1-only
- Same-day video visits in all 50 states
- Works with insurance for most plans
We may earn a commission when you sign up.
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| Sermorelin | $150 - $350/mo | Withdrawn (off-label use continues) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Merck-Serono voluntarily withdrew sermorelin (branded as Geref) in 2008 for business reasons, not safety. The pediatric GH deficiency market was small and recombinant HGH was winning. That withdrawal is frequently misread as a safety signal, but the FDA did not pull the drug - the manufacturer simply stopped producing it. Sermorelin remains legal to prescribe off-label through 503A compounding pharmacies, which is how legitimate anti-aging and HRT clinics still use it today.
Structurally yes. CJC-1295 is sermorelin with four amino acid substitutions (D-Ala, Gln, Ala, Leu) that resist enzymatic degradation and extend half-life from about 10 minutes to 30+ minutes for no-DAC, or roughly a week for DAC version. Both hit the same GHRH receptor. The modifications make CJC-1295 more potent per injection and less frequent dosing, but they also take it outside the grandfathered pharmaceutical history that protects sermorelin's compounding status.
Not usually. Sermorelin is off-label for adult anti-aging use, which most primary care doctors will not prescribe. The legitimate pathway is through anti-aging or hormone replacement clinics that partner with 503A compounding pharmacies. Expect an initial consult with blood work (IGF-1, growth hormone, full thyroid panel), then a monthly program running $150-350 through the clinic. Telehealth providers in the HRT space also prescribe it, with varying levels of diligence.
In February 2026 the FDA announced that several peptides currently on Category 2 - including CJC-1295, BPC-157, ipamorelin, and others - are under review for potential reclassification. The outcome could move some compounds back to compoundable status, keep others restricted, or formalize a new category. The review is expected to conclude within 12-18 months of the announcement. Sermorelin is not part of that review because it never entered Category 2.
CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. Sermorelin works via Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH. They differ in FDA approval status, efficacy data, and cost.
CJC-1295 typically costs $35 - $70/mo, while Sermorelin costs $150 - $350/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). Sermorelin is not FDA-approved (Withdrawn (off-label use continues)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of Sermorelin include Injection site reactions, Flushing, Headache. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideSermorelin is a bioidentical synthetic version of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of the full 44-amino acid GHRH molecule. It was previously FDA-approved...
View Full Sermorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between CJC-1295 and Sermorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.